[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004108898A3 - Transfection agents - Google Patents

Transfection agents Download PDF

Info

Publication number
WO2004108898A3
WO2004108898A3 PCT/US2004/017612 US2004017612W WO2004108898A3 WO 2004108898 A3 WO2004108898 A3 WO 2004108898A3 US 2004017612 W US2004017612 W US 2004017612W WO 2004108898 A3 WO2004108898 A3 WO 2004108898A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
genes
compositions
cell
methods
Prior art date
Application number
PCT/US2004/017612
Other languages
French (fr)
Other versions
WO2004108898A2 (en
Inventor
Robert Connor
Joseph Mcauliffe
Original Assignee
Canji Inc
Robert Connor
Joseph Mcauliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc, Robert Connor, Joseph Mcauliffe filed Critical Canji Inc
Priority to CA002528136A priority Critical patent/CA2528136A1/en
Priority to EP04754260A priority patent/EP1629085A2/en
Priority to AU2004245995A priority patent/AU2004245995A1/en
Priority to JP2006515161A priority patent/JP2007526219A/en
Priority claimed from PCT/US2004/017788 external-priority patent/WO2004108088A2/en
Publication of WO2004108898A2 publication Critical patent/WO2004108898A2/en
Publication of WO2004108898A3 publication Critical patent/WO2004108898A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides compounds, compositions and methods that enhance the transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The compounds, compositions and methods are useful for introducing agents such as genes into individual cells, as well as cells that are present as a tissue or organ.
PCT/US2004/017612 2003-06-04 2004-06-04 Transfection agents WO2004108898A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002528136A CA2528136A1 (en) 2003-06-04 2004-06-04 Transfection agents
EP04754260A EP1629085A2 (en) 2003-06-04 2004-06-04 Transfection agents
AU2004245995A AU2004245995A1 (en) 2003-06-04 2004-06-04 Transfection agents
JP2006515161A JP2007526219A (en) 2003-06-04 2004-06-04 Transfection drug

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US60/475,926 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy
US10/455,215 2003-06-04
USPCT/US04/17788 2004-06-04
PCT/US2004/017788 WO2004108088A2 (en) 2003-06-04 2004-06-04 Methods and compositions for interferon therapy

Publications (2)

Publication Number Publication Date
WO2004108898A2 WO2004108898A2 (en) 2004-12-16
WO2004108898A3 true WO2004108898A3 (en) 2006-04-27

Family

ID=33514684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017612 WO2004108898A2 (en) 2003-06-04 2004-06-04 Transfection agents

Country Status (2)

Country Link
JP (1) JP2007262081A (en)
WO (1) WO2004108898A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
TR201910060T4 (en) 2001-12-20 2019-07-22 Merck Sharp & Dohme SYN3 compositions and methods.
US8329681B2 (en) 2005-08-11 2012-12-11 University Of Massachusetts Methods and compositions for the efficient delivery of therapeutic agents to cells and animals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells

Also Published As

Publication number Publication date
JP2007262081A (en) 2007-10-11
WO2004108898A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2003087367A3 (en) Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
EP1507005A3 (en) Antisense modulation of BCL-X expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
CY1109367T1 (en) COMPOSITIONS AND METHODS FOR STRENGTHENING THERAPEUTIC INDICATORS
EP1709195A4 (en) Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
WO2004108899A3 (en) Pni microarray and uses
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
CA2259123A1 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
WO2005023305A3 (en) Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
WO2005040388A3 (en) Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
MXPA01008137A (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase.
EP1224202A4 (en) Antisense modulation of integrin-linked kinase expression
WO2001023541A3 (en) Compositions and methods for altering gene expression
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
WO2004108898A3 (en) Transfection agents
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2000036113A3 (en) Extending graft survival by heme oxygenase-i expression induced immunomodulation
EP1144690A4 (en) Antisense modulation of cellular inhibitor of apoptosis-2 expression
WO2004010956A3 (en) Antisense modulation of lar expression
EP1163373A4 (en) Antisense modulation of cellular inhibitor of apoptosis-1 expression
WO2001002020A3 (en) Compositions and methods for targeted enzymatic release of cell regulatory compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019510.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006515161

Country of ref document: JP

Ref document number: PA/a/2005/012978

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2528136

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 543969

Country of ref document: NZ

Ref document number: 2004754260

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004245995

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004245995

Country of ref document: AU

Date of ref document: 20040604

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004245995

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004754260

Country of ref document: EP